$BFLY

Edward Via College of Osteopathic Medicine (VCOM) and Butterfly Network (BFLY) will equip all VCOM students with Butterfly iQ3 ultrasound devices, starting with the 2026 class. The partnership aims to enhance ultrasound education and rural healthcare. BFLY will provide discounted devices and track usage through the Lighthouse Program. VCOM graduates 660 physicians annually, many serving rural areas.

Neuralink, a private brain-computer interface (BCI) company, successfully helped a patient with ALS communicate. Investors cannot buy Neuralink, but two public companies, Quantum-Si (QSI) and Butterfly Network (BFLY), are connected to the BCI field. QSI makes research tools and saw a 7x volume spike, while BFLY supplies ultrasound chips to BCI developers like Merge Labs and Bridge Neurotech.

Butterfly Network (BFLY) stock rose 1.6% pre-market after Canaccord Genuity initiated coverage with a Buy rating and $10 target, citing its ultrasound tech and AI capabilities. Analysts highlight new products and partnerships. The stock has seen positive analyst activity, with a consensus target of $11.40. Q3 earnings are due October 29.

Butterfly Network (BFLY) has signed a multi-year R&D and licensing deal with Bridge Neurotech. The agreement allows Bridge to use Butterfly's Ultrasound-on-Chip tech for non-invasive brain-computer interfaces. The deal includes milestone payments and hardware purchase commitments, according to the company.

Butterfly Network (BFLY) appointed Michael Noonen to its board, effective October 9, 2026, and added him to the Compensation and Technology Committees. This increases the board size to seven directors. Noonen is independent under NYSE standards and has not previously held positions with the company.

Butterfly Network, Inc. (BFLY) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Butterfly Network Appoints Mike Noonen to Board of Directors Seasoned Semiconductor Leader Brings Three Decades of Experience Scaling Chip Companies NEW YORK & BURLINGTON, Mass.-- October 5, 2026 -- Butterfly Network, Inc. (NYSE: BFLY) ("Butterfly"), a pioneer and le

Evercore ISI initiated coverage on Butterfly Network (NYSE: BFLY) with an outperform rating and $15.00 price target, citing its ultrasound-on-chip technology and growth potential. The firm projects $550M+ revenue by 2030 and positive EBITDA by 2028. BFLY stock has risen 367% over the past year, trading at $9.15 with a $2.44B market cap. Q2 2026 results showed a smaller loss than expected but lower revenue. Needham also initiated coverage with a buy rating and $10.00 target.

Analysts have issued ratings for five stocks: W. P. Carey (WPC) received a Buy rating with a $73 target, citing restructuring and sector valuation. Eldorado Gold (EGO) was upgraded to Buy with a $54 target, highlighting growth prospects. GE Healthcare (GEHC) got a Buy rating with a $93 target, expecting growth in imaging and software. Butterfly Network (BFLY) was rated Buy with a $10 target, citing its ultrasound technology.

Butterfly Network (BFLY) stock rose 11.5% after Needham initiated coverage with a Buy rating and $10 target, citing its ultrasound tech and Embedded business model. TD Cowen also has a Buy rating and $10 target. BFLY's Q3 revenue grew 39% YoY, with Embedded segment growth and expanding margins. The broader market had minimal impact on BFLY's surge.

Butterfly Network's (BFLY) CAO, Megan Carlson, sold 13,804 shares for over $100,000 to cover tax withholding. She retains 412,000 shares. BFLY's stock rose 381% in the past year, with a $2.1B market cap and $112.1M TTM revenue, but has a -40% return since 2021.